PPARG and diabetic peripheral angiopathy: As an agonist of peroxisome proliferator-activated receptor-γ (PPARγ), Rosiglitazone was reported to suppress vascular endothelial cell activation and injury by inhibiting mitochondrial oxidative stress and dysfunction through heat shock protein 22 (HSP22)-dependent regulation of PPARγ in diabetes angiopathy [133].